Memorable trades executed with commentaries for this week.
December 16, 2024 to December 20, 2024 4:00 PM
For this week the initial hypothetical investment of $10,000 turned into a LITTLE FAT LOSS of $3,364 (that's right $3,364 … the G-101 SPM AI algorithm failed) and blame it on $MU (Micron Technology Inc.) from its common stock and call options. Luckily, the other memorable trades had a $54,537 in gain to offset the Micron call options fiasco.
Since presenting “Weekly Review,” we had five weeks of outrageous gains from the companies of our memorable trades. Hopefully, the fully documented results as stated may not represent future transactions, and we immediately return to our winning ways by making our MONEY TALK.
When you peruse our performance this week, we had some BIG WINS, but in the end the Micron trades broke the bank.
PART ONE
12.20.24
$IONQ $$46.41 +8.62. *DAC (dollar average cost includes partial sales to reduce cost to zero.)
CHANGE EXIT TO $65.00 FROM $50.00 (maintain Legacy Holding status).
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.20.24
$RGTI $10.03 +2.55. DAC (dollar average cost includes partial sales of long position to reduce net cost to zero). CHANGE EXIT TO $15.900 from $10.00. BRIEF: Craig-Hallum analyst Richard Shannon initiates coverage on Rigetti Computing(RGTI) with a Buy rating and announces Price Target of $12. Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.20.24
OPTIONACTION
$MU $84.68 bid.
TAKE CALL OPTIONS LOSS
12.20.24
FLASHTRADE
$HSDT $1.25 SELL/ TAKE PROFIT
____________________________________________
$HSDT $0.6105 BUY/NEW LONG POSITION carries "day trade tag" to $1.25 HIGH RISK.
12.19.24
$OKLO $21.46 bid. DAC (dollar average cost) (2) 20.26 / last $18.85 (12.18.24. EXIT $40.00.
UPDATE: Wedbush analysts-initiated coverage with an Outperform rating, citing the nuclear-power startup’s “momentum into 2025” and its ability to benefit from the artificial-intelligence boom. Analysts led by Daniel Ives set a target of $26 for the price
12.19.24
$VRAR $4.50 +1.26. DAC (dollar average cost) $1.00 (12.10.24).
CHANGE EXIT TI $10.00 FROM $2.50.
BRIEF: Today announced that its subsidiary company Brightline Interactive, LLC ("BLI") has entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025.
Lyron Bentovim, President and CEO of Glimpse, commented: "In partnership with the US Navy, we believe that the Immersive Simulator represents a key milestone in the world of advanced simulation technology, building on the momentum around Brightline's vision for the SpatialCore platform."
12.19.24
$MNMD $7.50 bid. DAC (dollar average cost) $5.855 (9.10.24). EXIT $11.00.
BRIEF: Today announced that it will be added to the Nasdaq Biotechnology Index ($NBI), effective at market open on Monday, December 23, 2024.
“2024 has been a transformational year; we’ve successfully executed many important milestones, including raising approximately $250 million through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet (ODT) and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for major depressive disorder, and most recently, launching Voyage, our Phase 3 study of MM120 ODT in generalized anxiety disorder,” said Rob Barrow, Chief Executive Officer . “We are in a pivotal phase in our growth and the addition to the NBI further validates our potential in delivering long-term value to shareholders as we progress our pipeline."
12.18.24
$MU $90.75 HOLDING LONG POSITION AND OPTIONS UPDATE: Micron beats by $0.03, reports revs in-line; guides Q2 EPS below consensus, Reports Q1 (Nov) earnings of $1.79 per share, 0.03 better than the consensus of $1.76; revenues rose 84.3% year/year to $8.71 bln vs the $8.71 bln consensus. ^Data center revenue grew over 40% sequentially and over 400% year over year. ^Non-GAAP gross margin of 39.5% compared to 36.5% in Q4. Co issues downside guidance for Q2, sees EPS of $1.43, +/- $0.10, equating to $1.33-$1.5 vs. $1.91 consensus; sees Q2 revs of $7.90 bln, +/- $200 mln, equating to $7.70-$8.10 bln vs. $8.94 bln. "... We continue to gain share in the highest margin and strategically important parts of the market and are exceptionally well positioned to leverage AI-driven growth to create substantial value for all stakeholders." Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$MU $86.34 ask. BUY/ADD TO OPEN POSITION INCLUDING OPTIONS. EXIT $125.00 midterm.
OPTIONACTION
ADD TO CALL POSITION.
$MU 106.32 bid carries SPM 88.01 tag to $115.00 in near term BUY CALL OPTION MU December 27, 29024 $110.00 CALL at $5.20 ask DAC (dollar average cost) (2) $6.325.
OPTIONACTION
$MU $109.41 bid carries SPM 87.68 tag to $115.00 in near term BUY CALL OPTION MU December 27, 29024 $110.00 CALL at $7.45 ask.
12.18.24
$VUZI $4.46 +$0.62. DAC (dollar average cost) $0.965 (9.9.24).
CHANGE EXIT TO $8.00 as Second Tier - * Retain pre-Legacy Holding status..
Update: Vuzix enters into an agreement with Augmex, a one-stop-shop solutions provider for increasing productivity with smart glasses.
NOTE: Vuzix has received and shipped against an initial six-figure order from Augmex, who will bundle their software with Vuzix products as a solution to its supply chain customers across Europe.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.18.24
OPTIONACTION
$BA 176.11 +3.14
HOLD CALL OPTIONS
SELL CALL OPTIONS/TAKE PROFIT
$BA December 20, 2024 $160.00 CALLS at $16.25 bid.
DAC (dollar average cost) $8.45 (10.23.24).
12.18.24
$BBAI $3.30 bid. SELL/TAKE PROFIT ON REARCHING EXIT TARGET.
DAC (dollar average cost) (4) $1.475 / last $1.78 (8.21.24).
12.18.24
$APLD $9.86 bid. DAC (dollar average cost) $6.81 (13.00).
BRIEF: Co announced the successful energization of its on-site main substation transformer. This milestone signals the facility's progression into the next stage of its build-out, setting the foundation for a data center capable of supporting cutting-edge AI and high-performance computing.
12.18.24
$VRAR $1.97 bid. DAC (dollar average cost) $1.00 (12.10.24). EXIT $2.50.
BRIEF: , today issued a letter to shareholders from its President & CEO, Lyron Bentovim, summarizing key Glimpse developments for Calendar Year 2024.
"2024 was a transformational year for Glimpse, in which we made significant strides in our strategic transition to focus on providing enterprise-scale Spatial Computing, Cloud and AI driven Immersive middleware software and solutio - led by our subsidiary company Brightline Interactive. This successful transition included major contracts with leading U.S. Department of Defense ("DoD") and other large entities, while working directly with Nvidia, Microsoft, Cesium and many others.
The Immersive industry itself also made important progress in 2024, with major initiatives and products announced by Apple, Meta, Nvidia, Google, Samsung, Snap and others. These bode well for the Immersive industry in general and for Glimpse in particular.
12.17.24
$NRDY $2.04 bid. DAC (dollar average cost) (11) $1.11 / last $$0.942 (8.9.24).
CHANGE TO $3.50 FROM $2.50.
BRIEF: Chief Executive Officer bought 5,300,000 shares of Class A Common Stock at $1.51 - $2.05 worth about $9.6 mln (transaction dates 12/12-12/16).
12.17.24
$IONQ $40.65 . SELL/TAKE PROFIT on 25% of original position/current net holding is 50%. Maintain EXIT status at $50.00.
*DAC (dollar average cost includes partial sale of long position to reduce cost to zero).
Original BUY was at $15.53 on 8.11.23 as Legacy Holding status to $50.00 EXIT.
BRIEF:
________
^^ $15.53 (8.11.23) BUY
^^ $10.58 (1.18.24) BUY - add to position
^^ $ 9.91 (2.29.24) BUY - add to position
^^ $ 7.39 (4.16.24) BUY - add to position
^^ $23.95 (11.08.24) SOLD 25%.
^^ $40.65 (12.17.24) SOLD 25%
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.17.24
$TNXP $0.74 bid. SELL/TAKE PROFIT ON ENTIRE LONG POSITION on weaker SPM tag / issue is future dilution. PLAN TO REVISIT.
*DAC (dollar average cost) $0.16388/ last BUY $0.153 (10.16.24).
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.16.24
$LAES $3.19 bid. SELL/TAKE PROFIT on compromise SPM tag.
* DAC (dollar average cost) $1.175 (12.11.24).
PLAN TO REVISIT.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.16.24
$TNXP $0.466 +0.2237 bid. DAC (dollar average cost) $0.16388 (10.16.24). EXIT $1.75.
UPDATE: Today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights.
Submitted New Drug Application to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies
^Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women
^Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years
^Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA
12.16.24
$LYFT $14.14 bid. DAC (dollar average cost) $11.27 (9.11.24). EXIT $26.00.
BRIEF: BofA's Michael McGovern commented, "Lyft CEO David Risher posted on X over the weekend: "SF is a growing market for rideshare. Even with Waymo on the road, our market share remains strong. Lyft mgmt. also spoke at a conference last week, suggesting SF growth was steady, adding that "we are in all of the right conversations" and "you can expect more from us" on partnerships, as traditional rideshare networks provide marketplace management (tech & ops support) that AV OEMs can leverage to drive higher utilization. At the same conference, Uber mgmt. noted bookings growth in SF exceeds US growth rates, despite Waymo's growth, and AVs are key to growing supply long-term, with rideshare penetration still only at 20% potential riders. Uber also noted that their Waymo scale in Austin and Atlanta will be in the "hundreds of vehicles" in each city, a significant scale."
12.16.24
OPTIONACTION
$BA $173.64 +4.05
HOLDS CALL OPTIONS
$BA December 20, 2024 $160.00 CALLS
*DAC (dollar average cost) $8.45 (10.23.24)
CUREENT VALUE $12.55 bid.
BRIEF: The Boeing Company BA recently announced plans to invest $1 billion to expand its plant in Charleston County, SC. The expansion aims to double the production volume of 787 Dreamliners to 10 units per month from the current levels by 2026.
note: The facility has been running since 2009 and is crucial for making and delivering the 787 Dreamliner. The expansion is expected to be ready by early 2027.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.16.24
$QURE $16.98 +1.58 bid. DAC (dollar average cost includes partial sale to reduce cost to $6.25). EXIT $28.00 - Legacy Holding status.
BRIEF: Stifel Maintains Buy on uniQure, Raises Price Target to $32 from $12.00.
12.16.24
$RGTI $8.49 bid +1.33. SELL 15% OF LONG POSITION/TAKE PROFIT TO RECOVER ORIGINAL COST.
* DAC (dollar average cost was $1.093 / last BUY was at $0.7912 (10.7.24). EXIT $10.00.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
12.16.24
$RXRX $7.53 bid. DAC (dollar average cost) $6.50 (8.8.24). EXIT $10.00.
OVERVIEW: AI-based drug discovery is one of the biggest trends major companies and venture capitalists are betting on. Some estimates suggest AI-led drug discovery could soon be a $100 billion business. Recursion Pharmaceuticals is an AI drug discovery play; high-dimensional data and predictive results for drug discovery and development.
note: $NVDA invested $50 million in Company.
12.16.24
$EBS $8.80 bid. DAC (dollar average cost including partial liquidation of position reduces net cost to zero). EXIT $20.00.
UPDATE: Emergent BioSolutions announces that the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services has awarded a $50 mln option to Emergent’s existing contract for the acquisition of CYFENDUS.
12.16.24
OPTIONACTION
$GIS $66.92 +1.42 bid.
* HOLDS CALL OPTIONS
$GIS December 20, 2024 $$70.00 CALLS at $0.28
OVERVIEW: General Mills will release earnings results for its second quarter ( EB12.18).
^ Expects to report quarterly earnings at $1.22 cents per share, down from $1.25 per share in the year-ago period; projects to report revenue of $5.14 billion for the recent quarter, compared to $5.14 billion a year earlier, according to SPM tag data.
^ B of A Securities analyst Bryan Spillane upgraded the stock from Neutral to Buy and raised the price target from $78 to $80 on Dec. 13; analyst accuracy rate of 63%.
^Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and cut the price target from $77 to $70 on Nov. 15; analyst accuracy rate of 61%.
^JP Morgan analyst Ken Goldman maintained a Neutral rating and increased the price target from $63 to $67 on Oct. 14; analyst accuracy rate of 76%.
* Click SEARCH icon on our landing page to review the postings.
12.16.24
$MNMD $7.33 bid. DAC (dollar average cost) $5.855. EXIT $11.00.
UPDATE: Today announced first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT versus placebo and is expected to enroll approximately 200 participants in the United States. The Panorama study, the second Phase 3 trial, will be conducted in the U.S. and Europe and is on track to initiate in the first half of 2025.
"Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people1 in the U.S. living with GAD.... our Phase 3 studies are designed to adhere to the highest clinical and ethical standards and are in alignment with guidance from the U.S. Food and Drug Administration," said Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed.
12.16.24
$LAES $2.56 bid. DAC (dollar average cost) $1.175 (12.11.24). EXIT $5.00. OVERVIEW: Closing today securities purchase agreement with several institutional investors to purchase 7,692,308 ordinary shares at a public offering price of $1.30, for gross proceeds of $10.0 million; utilize the to fund the deployment of its next-generation post-quantum semiconductor technology and ASIC capabilities in the United States, to support working capital and for general corporate purposes. note: Using quantum technology to the rapidly expanding market of professional drones and Unmanned Aerial Vehicles and professional drones. SEALSQ has already established strategic partnerships with several drone manufacturers, including Parrot and AgEagle, to deliver security solutions for unmanned aerial systems. As Europe’s leading commercial UAV provider, Parrot has already integrated SEALSQ’s secure chips into its flagship models, including the ANAFI USA, ANAFI Ai, and SKYCONTROLLER 4.
PART TWO
Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate, and culminating with the issuance of an auxiliary SPM tag.
^Follow the daily abstracts: SPMNOTES, FIRSTLOOK, OPTIONACTION, INSIDERS, DILUTION, SHOWTIME, NOISE, FLASHTRADE, QUESTIONBOX and SURVEY.
^DAC means “dollar average cost” and determines the true cost of the investment position during the cycle of the trade.
IDEA: Devote quality time to understand how to apply the data as a "positional investor."
* Click https://stocktwits.com/G101SPM SEARCH on (magnifying glass) icon on our landing page to review the postings.
MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior than the other kinds. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. In the process we have become Number One in non-human investment/enterprise analytics.
Our tools do more than process data, G-101 SPM AI generates world-class content, fully automates workflows, and unlocks insights in ways traditional AI can never achieve.
WE'LL MATCH OUR TRACK RECORD TO ANYONE OR TO ANY THING.
To date not one firm or individual has challenged us or even matched or questioned our transparence.
"I guess when you're the best, you're the best!"
Comments